Gene editing

#CRISPR #Gene editing #Genetic modification #Mouse models

With so many technologies for genetically modifying models, it pays to choose wisely

Listen to this article on the DDW Podcast: By Caroline Horizny, Taconic Biosciences When a pharmaceutical company, biotech firm, or academic institution embarks on a preclinical research project, one of the most critical early-stage decisions is which animal model will best support the project’s objective. Mouse models remain a go-to resource… Read More

#Exclusive Content

#CRISPR #Gene editing #Life sciences #Therapeutics

Horizon Discovery extends gene modulation portfolio

Horizon Discovery, a PerkinElmer company, announced that it is expanding its gene editing and modulation portfolio to include a new family of CRISPR modulation (CRISPRmod) reagents for CRISPR interference (CRISPRi). CRISPRi enables scientists to better understand the biological pathways, processes and pathologies of disease by repressing genes at the transcriptional… Read More

#News

#Gene editing #iPSC #Therapeutics

Horizon applies expertise for iPSC cell line engineering services

The development of therapeutic treatments is a challenging process linked to understanding mechanisms that underly human disorders. Finding the relevant biological model has been a limiting process so far. The development of induced pluripotent stem cell (iPSC) technology has revolutionised the way we study complex disorders. iPSCs offer a unique… Read More

#News

#Gene editing #Stem cells

Single-cell cloning technology from iotaSciences at SLAS2021

iotaSciences, a company that develops technologies for single-cell cloning is giving exhibitor tutorials at SLAS2021 Digital. These tutorials will explore some of the key challenges of single-cell cloning for gene editing, stem cells and other applications. During the tutorials we will introduce our new cloning platform and provide customer data… Read More

#News

#Analysis #Biologics / Biotechnology #Business #Cell therapy #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene editing #Gene therapy #Genetics / genomes #Immunology #In Silico Biology #Lead discovery #Protein chemistry / Proteomics #RNA #Stem cells #System biology #Systems biology #Therapeutics

Will the next generation of CAR-T cells be modified using base editing?

By Dr Jamie Freeman Base editing is a potentially transformative technology for engineering DNA in cells that has the potential to generate knockouts or correct certain errors or mutations in the DNA for applications such as cell or gene therapies. Compared with currently-available gene editing methodologies such as CRISPR/Cas9, which… Read More

#Exclusive Content

#Business #Gene editing #High throughput screening #Lead discovery #RNA #Screening

Horizon Discovery streamline CRISPR gene editing workflows

Horizon Discovery Group plc, a global leader in the application of gene editing and gene modulation technologies, today announced the addition of predesigned synthetic single guide RNA (sgRNA) to its product range. The sgRNAs, available individually or as library collections, expand the Company’s Edit-R gene engineering… Read More

#News

#Academic #Assay development optimisation & technology #Business #Cell therapy #Cellular assays #Chemical engineering #Clinical trials #Drug development #Drug discovery #Enabling technologies #Gene editing #Gene therapy #Genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Microfluidics #Oncology #RNA #Screening #Stem cells #Therapeutics #Toxicology #Translational #Translational chemistry

Merging two immunotherapies may be more effective treatment against some cancers

Some of the most promising advances in cancer treatment have centred on immunotherapies that rev up a patient’s immune system to attack cancer. However, immunotherapies don’t work in all patients, and researchers have been searching for ways to increase their effectiveness. Now, researchers at Washington University School of… Read More

#Cancer Research #News

#Academic #Assay development optimisation & technology #Business #Cellular assays #Drug development #Drug discovery #Enabling technologies #Gene editing #Genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Microfluidics #Precision medicine #Preclinical #Screening #Stem cells #Therapeutics #Translational #Translational chemistry

British Patient Capital invests in life-changing biotech companies

British Patient Capital is committing $65m to SV Health Investors’ latest fund, SV7 Impact Medicine Fund (IMF), to turn scientific breakthroughs into biotech companies producing high impact precision medicine drugs for poorly treated diseases. The commitment increases British Patient Capital’s exposure to life sciences and health technology, building… Read More

#Covid-19 #News

#Academic #Assay development optimisation & technology #Business #Cellular assays #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene editing #Genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Microfluidics #Molecular medicine #Oncology #Pathology #Precision medicine #Regulatory #RNA #Screening #Sequencing #Stem cells #Therapeutics #Translational #Translational chemistry

Quantro Therapeutics offers breakthrough oncology drug discovery platform

21 July 2020 Image: Anshu A Thanks to seed financing from Boehringer Ingelheim Venture Fund (BIVF) and Evotec, Quantro Therapeutics will generate a drug discovery pipeline, aiming to transform the precision and scope of cell-based compound screens. With the introduction of ‘Transcriptional Fingerprinting’ to drug discovery, Quantro intends… Read More

#News

#Academic #Business #Cellular assays #Drug development #Drug discovery #Enabling technologies #Gene editing #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Microfluidics #RNA #Screening #Stem cells #Therapeutics #Translational #Translational chemistry

UK pharma body says COVID-19 vaccine may still be many months away

Image: Dimitri Houtteman A COVID-19 vaccine being developed by Oxford University and AstraZeneca has generated an immune response in a study of roughly 1,000 patients, according to interim results. The Association of the British Pharmaceutical Industry (ABPI) has responded to the results of the Oxford – AstraZeneca vaccine… Read More

#Covid-19 #News

#Academic #Analysis #Assay development optimisation & technology #Biologics / Biotechnology #Business #Cellular assays #Drug development #Drug discovery #Enabling technologies #Gene editing #Genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Microfluidics #Protein chemistry / Proteomics #Screening #Stem cells #Therapeutics #Translational #Translational chemistry

Sphere Fluidics and Heriot-Watt University develop droplet generator instrumentation

20 July 2020 Image: Toa Heftiba Sphere Fluidics and Heriot-Watt University have been awarded a Knowledge Transfer Partnership (KTP) grant from Innovate UK, the UK’s innovation agency. The grant will facilitate the development of novel droplet generator instrumentation, which will be used to expand Sphere Fluidics’ portfolio of… Read More

#News

#Academic #AI / data analytics / healthtech / informatics #Assay development optimisation & technology #Biologics / Biotechnology #Business #Cell culture #Cellular assays #Drug development #Drug discovery #Enabling technologies #Gene editing #Genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Microfluidics #Screening #Stem cells #Therapeutics #Translational #Translational chemistry

Merck opens its largest M Lab Collaboration Centre in Shanghai

14 July 2020 Image: Denys Nevozhai Merck has opened its M Lab Collaboration Centre in Shanghai, the largest of the company’s nine centres worldwide. “With the booming pharmaceutical industry in Asia and greater emphasis on novel drug therapies, we see an increase in R&D on leading-edge treatments including… Read More

#News

#Business #Drug discovery #Gene editing #Genetics / genomes #RNA #Target validation

Horizon Discovery introduces Cas9 and dCas9-VPR stable cell lines

9 July 2020 Horizon Discovery Group has introduced stably expressing Cas9 and dCas9-VPR cell lines to help accelerate gene knockout and gene activation experiments, respectively. The cell lines are optimised to work alongside Horizon’s Edit-R predesigned synthetic single guide RNA (sgRNA) and CRISPRa guide RNA, offering researchers a… Read More

#News

#Academic #Assay development optimisation & technology #Business #Cellular & Molecular biology #Cellular assays #Chemical engineering #Drug development #Drug discovery #Enabling technologies #Gene editing #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Lead discovery #Microfluidics #Molecular medicine #RNA #Screening #Stem cells #Therapeutics #Translational #Translational chemistry

Cell ‘membrane on a chip’ could speed up screening of drug candidates for COVID-19

Researchers have developed a human cell ‘membrane on a chip’ that allows continuous monitoring of how drugs and infectious agents interact with our cells. It may soon be used to test potential drug candidates for COVID-19. The researchers, from the University of Cambridge, Cornell University and Stanford University,… Read More

#Covid-19 #News

#Academic #AI / data analytics / healthtech / informatics #Assay development optimisation & technology #Biologics / Biotechnology #Business #Cellular assays #Chemical engineering #Chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene editing #Genomics #High Content Screening #High throughput screening #Imaging #Medicinal chemistry #Microfluidics #Screening #Stem cells #Therapeutics #Translational #Translational chemistry

PharmEnable raises £1.8 million for drug discovery expansion

30 June 2020 Image: Lucas Vasques PharmEnable, has closed a £1.8 million seed financing to support its transition into a drug development company. The Cambridge, UK-based drug discovery company uses advanced medicinal chemistry and AI-enabled approaches to design the next generation of highly complex and specific drug candidate… Read More

#News

#Cell therapy #Gene editing #Gene therapy #High Content Screening #Stem cells

New paper published on gene editing technique in hematopoietic stem cells

30 June 2020 Image: National Cancer Institute The San Raffaele Telethon Institute for Gene Therapy (SR-Tiget) and Genespire have published data highlighting progress in the development of an improved targeted gene replacement technology in human hematopoietic stem cells (HSCs) in Nature Biotechnology. The paper, entitled Efficient gene editing of… Read More

#News